SAKK News
May 3 Swissmedic has accepted the trial GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas.The trial was opened for accrual at the first center, the Kantonsspital St.Gallen.
May 2 The trial SAKK 41/08: Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced, K-ras mutated rectal cancer. A multicentre phase I/II trial was closed for accrural as of 2.5.2013.
May 2 The trial SAKK 22/99 Randomized phase III trial of Herceptin® followed by chemotherapy plus Herceptin® versus the combination of Herceptin® and chemotherapy as palliative treatment in patients with HER2-overexpressing advanced/metastatic breast cancer was closed for accrural as of 02.05.2013.
April 29 Swissmedic has accepted the trial SAKK 22/10 / UNICANCER UC-0140/1207 A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer . The trial was opened for accrual at the first center, the Kantonsspital St.Gallen.
March 18 For trial HD18 for advanced stages. Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma: treatment stratification by means of FDG-PET” akzeptiert. an amendmend was issued. Hence the trial is open for accrural.Further information in the member section.
March 1 For trial STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. A multi arm multi-stage randomized controlled trial an amendment has been issued. The amendment was written in order to incorporate a new comparison arm (Arm H = hormone therapy + radiotherapy). Further information can be found in the members'section.
February 13 Swissmedic has accepted trial HD17 Treatment optimization trial in the first-line treatment of intermediate stage Hodgkin lymphoma; treatment stratification by means of FDG-PET notifiziert The trial was opened for accrual at the first center, Kantonsspital Liestal.
January 22 The trial STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy
A multi arm multi-stage randomized controlled trial was temporarily closed for accrual. Further information can be found in the members'section.
January 21 For trial CORAL 50-03B Randomized study of ICE plus rituximab (R-ICE) versus DHAP plus rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma, eligible for transplantation followed by randomized maintenance treatment with Rituximab an amendment has been issued. Further information can be found in the members'section.
January 14 For trial HD 18 (advanced stages) Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma: treatment stratification by means of FDG-PET an amendment has been issued. Further information can be found in the members'section.
December 14 The trial SAKK 24/09 Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative metastatic or locally recurrent breast cancer. A multicenter, randomized phase III trial was closed for accrual on December 14.
December 3 The trial SAKK 16/00 Preoperative chemoradiotherapy vs. chemotherapy alone in non-small cell lung cancer (NSCLC) patients with mediastinal lymph node metastases (stage IIIA, N2): A randomized prospective phase III trial was prematurely closed for accrual on December 3.
For more SAKK news: